Jeff Goater
InvestorPartner at The Column Group · Executive at Nilo Therapeutics · Board director at RYNE Biotechnology Inc. · Board director at Remix Therapeutics
Boston, Massachusetts
Writes $100K – $5M checks · typically $1.5M
Find your path to Jeff
404 people in our graph share verified history with Jeff — schools, employers, funds. One of them is your warm intro.
Scott BillerunlockedJeff: together at Remix Therapeutics (2023–2026)
×2Jeff: together at Evercore
×2Jeff: together at Cowen & Company
Jeff: together at Voyager Therapeutics, Inc.
About
Jeff Goater leverages a career from research scientist to Evercore investment banker to biotech CEO, bringing deep technical, company-building expertise and a hands-on style as executive chair or interim CEO.
Contact· self-published, not guessed
Likely email· guessed from name + firm domain, not firm-published
- j•••@thecolumngroup.comreveal100% confident
Invests in
BiotechHealthtech
Executive at Nilo Therapeutics
Intro paths
→
In turn, Jeff can intro founders to Nilo Therapeutics's investors below.
Board director at RYNE Biotechnology Inc.
Intro paths
→
In turn, Jeff can intro founders to RYNE Biotechnology Inc.'s investors below.
RYNE Biotechnology Inc.'s investors · 2
Board director at Remix Therapeutics
Intro paths
→
In turn, Jeff can intro founders to Remix Therapeutics's investors below.
Remix Therapeutics's investors · 5
Co-founders at Remix Therapeutics
PS
Peter Smith, PhDCo-Founder, President and Chief Executive Officer
PS
Peter SmithCo-Founder, President and Chief Executive Officer
Experience
- Judo BioBoard Membercurrent2026 — present
- Judo BioExecutive Chair2022 — 2026
- Tortugas NeuroscienceBoard Membercurrent2025 — present
- NILO TherapeuticsBoard Membercurrent2024 — present
- Kenai TherapeuticsBoard Membercurrent2024 — present
- The Column GroupPartnercurrent2024 — presentBoston, Massachusetts, United States
- The Column GroupVenture Partner2021 — 2023
- Remix TherapeuticsBoard Membercurrent2023 — present
- AviadoBioChaircurrent2023 — present
- KallyopeBoard Membercurrent2022 — present
- Topo TherapeuticsBoard Member2024 — 2026
- Atavistik BioBoard Member2021 — 2026Cambridge, Massachusetts, United States
- Atavistik BioInterim CEO2022 — 2023
- Ribon TherapeuticsBoard Member2021 — 2024Cambridge, MA
- Surface Oncology Inc.Board Member2018 — 2023Cambridge, Massachusetts, United States
- Surface Oncology Inc.CEO2018 — 2021Cambridge, MA
- Surface Oncology Inc.CBO2017 — 2018Cambridge, MA
- LogicBio TherapeuticsBoard Member2020 — 2022Lexington, Massachusetts, United States
- VaccinexBoard Member2013 — 2022
- Voyager Therapeutics, Inc.CFO2016Cambridge, MA
- Voyager Therapeutics, Inc.SVP, Finance & Business Development2013 — 2016Cambridge, MA
- Synageva BioPharma Corp.VP, Business Development2013Greater Boston
- Evercore PartnersManaging Director2013Greater Boston
- Evercore PartnersVP, Healthcare, M&A Advisory2008 — 2013
- Cowen & CompanyVP, Equity Research, Specialty Pharmaceuticals2004 — 2008
- VaccinexDirector, Business Development2000 — 2004
Skills & more
Corporate Finance8Start-ups9Corporate Development15Valuation6Mergers & Acquisitions27Due Diligence12Business Development23Licensing2Venture Capital7Investment Banking4M&A experience2Emerging Markets1
+4 more
Private EquityIPOFinancial ModelingBiotechnologyFrom Jeff's professional profile.
Deals · 2
RYNE Biotechnology Inc.Board seat
via The Column Group · filed Mar 2024 · $81.8M raise
Ribon TherapeuticsBoard seat
via The Column Group · filed Dec 2022 · $25M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Board seats
Per SEC Form D filings.
Colleagues at The Column Group
Aadit Shah
Principal at The Column Group
Arnav Mehta, MD, PhD
Venture Partner at The Column Group
Carla Daniel
Partner at The Column Group
Craig Parker
Venture Partner at The Column Group
David Goeddel
Managing Partner at The Column Group
David V. Goeddel, Ph.D.
General Partner at The Column Group
David V. Goeddel, PhD
Partner Emeritus at The Column Group
Hui Tian
Partner at The Column Group
Network2
Investors connected to Jeff in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Jeff Goater?
- Jeff Goater leverages a career from research scientist to Evercore investment banker to biotech CEO, bringing deep technical, company-building expertise and a hands-on style as executive chair or interim CEO.
- Where does Jeff Goater work?
- Jeff Goater is Partner at The Column Group and Executive at Nilo Therapeutics and Board director at RYNE Biotechnology Inc. and Board director at Remix Therapeutics.
- What does Jeff Goater invest in?
- Jeff Goater invests in Biotech, Healthtech.
- What check size does Jeff Goater write?
- Jeff Goater typically writes checks of $100K – $5M.
- What boards does Jeff Goater sit on?
- Jeff Goater holds tracked board seats at Remix Therapeutics, Ribon Therapeutics, RYNE Biotechnology Inc..
- Where did Jeff Goater go to school?
- Jeff Goater studied at University of Rochester - Simon Business School (MBA); University of Rochester School of Medicine and Dentistry (MS, Microbiology / Immunology); University of Rochester School of Medicine and Dentistry (MS, Pathology).
Founder mafias
University of Rochester mafia41
Also came through, then founded or led a company.
Craig DubitskyBAFounded Happyproducts +1Anis KallelBachelor's degreeFounded Kaoun +1Alex FeiszliBachelor of Arts (B.A.)Founded Netmaker +1Artur BergmanFounded Amplify PartnersSunil DhaliwalFounded SuplariDavid NarrowB.S.Founded Sonavex
+ 34 more
Evercore mafia18
Also came through, then founded or led a company.
Ken SenaSenior Managing Director, Global Head of Internet Research CoverageFounded Aiera +1Simon SeroussiMarket Research Analyst InternFounded SuiteOp +1Daniel JonesInvestment Banking AnalystFounded Medfin +1Fernando Lelo de Larrea H.VicepresidentFounded FondeadoraLucia HuangInvestment Banking AnalystFounded OsmindDivyang AroraSummer AssociateFounded Byte Kitchen
+ 11 more
Kallyope mafia6
Also came through, then founded or led a company.
Judo Bio mafia3
Also came through, then founded or led a company.
Remix Therapeutics mafia3
Also came through, then founded or led a company.
Same school
Also attended University of Rochester - Simon Business School64
Camila VieiraPartner, Head of Brazil at QED InvestorsAndy WeymannVenture Partner, Frontiers in Health & Bio Investments at Verve VenturesDeepali NangiaPartner at SpeedinvestWei JiangFounder & Managing Partner at CatchLight Capital PartnersOmar FarooquiDirector of Valuation at EJF VenturesTim JonesPartner at ICI
+ 58 more
Also attended University of Rochester School of Medicine and Dentistry9
Maia HightowerInvestor at EPIC VENTURESScott HornerManaging Director at dsm-firmenich VenturingRandy BockInvestor at Walnut Venture AssociatesSamantha Miller 🌱Founder at Cadence Health Liberate the PillElizabeth EvansExecutive Officer at VaccinexErnest S. SmithExecutive Officer at Vaccinex
+ 3 more
Also attended University of Rochester157
Michael OdaiCOO & General Counsel at Mosaic VenturesCamila VieiraPartner, Head of Brazil at QED InvestorsBryan CiambellaGeneral Partner at PROOFWilliam SheahanSenior Vice President and Chief Innovation Officer at Flare Capital PartnersArtur BergmanFounder, Fastly at Amplify PartnersNicole VitulloInvestor at Arboretum Ventures
+ 151 more
Shared employers
Also worked at Tortugas Neuroscience3
Also worked at NILO Therapeutics1
Also worked at Kallyope8
Josh WolfePartner and Co-Founder at Lux CapitalIan PeikonVenture Partner at Lux CapitalRami HannoushVenture Partner at Versant VenturesDusan PerovicPartner at Two Sigma VenturesAdam GoulburnFounder and Managing Partner at Dimension CapitalMayank AgrawalFounder at Proof of Human
+ 2 more
Also worked at Ribon Therapeutics9
Anja KoenigGlobal Head of NVF at Novartis Venture FundMarian NakadaVice President, Venture Investments at JJDCOliver WalkerManaging Partner at CGS Management AGAnja KönigGlobal Head at Novartis Venture FundChristian SchubertHead of AbbVie Ventures at AbbVieJodie MorrisonVenture Partner at Atlas Venture
+ 3 more